Barts Hospital, London Enrolls First Patients In ROX Medical's CONTROL-HTN Resistant Hypertension Trial
SAN CLEMENTE, Calif., March 25, 2013 /PRNewswire/ -- St Bartholomew's and the London NHS Trust (Barts) have enrolled their first patients in the ROX Medical CONTROL-HTN international randomized controlled hypertension trial. The CONTROL-HTN trial is evaluating the ROX FLOW procedure - creating a small connection between artery and vein in the upper leg - for the treatment of resistant hypertension. Dr. Mel Lobo and Prof. Mark Caulfield enrolled the first patients at Barts Hospital. The first two patients randomized to the treatment group received the ROX procedure successfully performed by Dr. Ajay Kumar Jain and Prof. Anthony Mathur from the Cardiology department.
"We are very excited to be part of this trial which could lead to a novel new therapy option for resistant hypertension," commented Dr. Lobo. "We are impressed with the ease of the procedure, the need for minimal anesthesia and like the fact that it is reversible."
ROX Medical's FLOW procedure is a minimally invasive, catheter procedure to place a small coupler between the artery and vein in the upper leg. The procedure reduces peripheral vascular resistance by diverting some of the higher-pressure arterial blood to the low pressure and highly compliant venous system; essentially restoring some of the lost compliance back into the vascular system. Because the FLOW procedure does not target the sympathetic nerves or arteries of the kidneys, it may be of benefit to those patients who either cannot have or have failed to respond to renal denervation. "Because the ROX FLOW procedure is reversible and leaves all other therapy options open, we are finding more patients and physicians who see this as a first choice device therapy option for resistant hypertension," commented ROX CEO Rodney Brenneman.
"Resistant hypertension patients are a challenge for hypertension specialists and there is a need for new therapy options," added Dr. Lobo. "We are looking forward to enrolling our next patients and watching their progress over the coming months."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV